• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Where's Waldo, I mean Pyott?









High overhead and low sales? Run into the ground? Not accurate.

If Pyott can be criticized, despite the 2400% stock price increase since coming in as CEO, IT WOULD BE FOR NOT LEVERAGING HIS BALANCE SHEET WITH A GOOD GROWTH COMPANY ACQUISITION.

The Scottish are notoriously frugal and love to horde money....jus sayin.

And a very poor pipeline. Less than adequate return on investment from Research and Development.
 




rip pyott all you want but he has done exactly what he is supposed to do..maximize share holder value...cant argue with the results...now everyone grow up and understand this is business, not a charity organization

the other stuff at this point is nothing but a distraction to current actavis and allergan employees but again this is capitalism at work...

happy holidays
 












rip pyott all you want but he has done exactly what he is supposed to do..maximize share holder value...cant argue with the results...now everyone grow up and understand this is business, not a charity organization

the other stuff at this point is nothing but a distraction to current actavis and allergan employees but again this is capitalism at work...

happy holidays

Another HR hussey.
 




Similar threads

Replies
0
Views
455
Replies
34
Views
10K
Allergan
anonymous
Replies
11
Views
5K